← All candidates
19 insider buys in the last year — $3.74M in all.
38 filings on record.
CRVOCervoMed Inc.
NasdaqCM · Healthcare · $38.86M
$2.45
-3.16% · Sep 15
19 insider buys in the last year — $3.74M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 19 buys◆ 21 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 5×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CRVO ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$38.86M
Float
9.6M
64% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
117.3
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Boger Joshua S
Bought $3.00M on Jun 11 — 955,414 sh @ $3.14, held indirect, 53% of their stake.
First Form 4 on file
10% owner
Gregoire Sylvie
Bought $91.4K on Nov 17 — 10,807 sh @ $8.46, held indirect, 87% of their stake.
0 of 1 position beat the S&P
CEO & President
Alam John J
Bought $91.4K on Nov 17 — 10,807 sh @ $8.46, held direct, 0.7% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
14 more transactions on Pro →Context
Wall St
$15.40 avg target
+528.6% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$0.64 act+$0.22
Q1 '26−$0.86 act−$0.07
Q4 '25−$0.88 act−$0.18
Q3 '25−$0.84 act−$0.20
Coverage
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools RallyStocktwits · 06-18CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)InvestorsHub · 06-18CervoMed Insiders Lose Out As Stock Sinks To US$2.45Simply Wall St. · 06-14Why Did CRVO Stock Crash 22% In Pre-Market Trading Today?
The file stays open
38 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice